On Dec. 13, 2021, the Coalition for Epidemic Preparedness Innovations, and Affinivax announced a partnership to advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.

CEPI will provide funding of up to $4.5 million to support the initial development of a vaccine candidate based on Affinivaxﾒs innovative Multiple Antigen Presenting System technology platform. CEPIﾒs investment in Affinivax will fund vaccine candidate design and selection, manufacturing process development and preclinical testing against specific SARS-CoV-2 variants.

CEPIﾒs 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a ﾓlibraryﾔ of vaccine candidates for use against known and unknown pathogens.